<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659631</url>
  </required_header>
  <id_info>
    <org_study_id>B7831001</org_study_id>
    <nct_id>NCT02659631</nct_id>
  </id_info>
  <brief_title>PF-06671008 Dose Escalation Study in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06671008 In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses
      of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin
      expression. The study will then expand to look at the selected dose in patients with
      P-cadherin expressing TNBC, CRC or NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2016</start_date>
  <completion_date type="Anticipated">March 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-Limiting Toxicities (DLT) [Part 1]</measure>
    <time_frame>Baseline through Day 21</time_frame>
    <description>First cycle DLTs in order to determine the maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with objective response</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Objective response as determined by RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>C1D1 0, 1, 2, 4, 8, 24, 48, 72, 96 hrs post, D8 0, 2, 4, 8, 24, 48, 72 hrs post, D15 0, 2 hrs post, C2D1 0, 2, 4, 8, 24, 48, 72 hrs post, D8 and D15 0, 2 hrs post, 0, 2 hrs post additional dosings, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>C1D1 0, 1, 2, 4, 8, 24, 48, 72, 96 hrs post, D8 0, 2, 4, 8, 24, 48, 72 hrs post, D15 0, 2 hrs post, C2D1 0, 2, 4, 8, 24, 48, 72 hrs post, D8 and D15 0, 2 hrs post, 0, 2 hrs post additional dosings, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>C1D1 0, 1, 2, 4, 8, 24, 48, 72, 96 hrs post, D8 0, 2, 4, 8, 24, 48, 72 hrs post, D15 0, 2 hrs post, C2D1 0, 2, 4, 8, 24, 48, 72 hrs post, D8 and D15 0, 2 hrs post, 0, 2 hrs post additional dosings, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to End of Dosing Interval (AUCtacu)</measure>
    <time_frame>C1D1 0, 1, 2, 4, 8, 24, 48, 72, 96 hrs post, D8 0, 2, 4, 8, 24, 48, 72 hrs post, D15 0, 2 hrs post, C2D1 0, 2, 4, 8, 24, 48, 72 hrs post, D8 and D15 0, 2 hrs post, 0, 2 hrs post additional dosings, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from time zero to infinity (AUCinf)</measure>
    <time_frame>C1D1 0, 1, 2, 4, 8, 24, 48, 72, 96 hrs post, D8 0, 2, 4, 8, 24, 48, 72 hrs post, D15 0, 2 hrs post, C2D1 0, 2, 4, 8, 24, 48, 72 hrs post, D8 and D15 0, 2 hrs post, 0, 2 hrs post additional dosings, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance or Apparent Clearance</measure>
    <time_frame>C1D1 0, 1, 2, 4, 8, 24, 48, 72, 96 hrs post, D8 0, 2, 4, 8, 24, 48, 72 hrs post, D15 0, 2 hrs post, C2D1 0, 2, 4, 8, 24, 48, 72 hrs post, D8 and D15 0, 2 hrs post, 0, 2 hrs post additional dosings, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response (Part 1)</measure>
    <time_frame>Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression, unacceptable toxicity, or up to 24 months</time_frame>
    <description>Response rate by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with PFS (Part 2)</measure>
    <time_frame>Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression or unacceptable toxicity, or up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with OS (Part 2)</measure>
    <time_frame>Baseline and every 6 weeks until disease progression or unacceptable toxicity, or up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titers of anti drug antibodies (ADA) and neutralizing antibodies against PF 06671008</measure>
    <time_frame>C1D1 0 hrs, D15 0 hrs, and C2D1 0 hrs, and D1 0 hrs post additional dosings, up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>PF-06671008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06671008</intervention_name>
    <description>Dose Escalation Phase - Part 1</description>
    <arm_group_label>PF-06671008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06671008</intervention_name>
    <description>Dose Expansion Phase - Part 2</description>
    <arm_group_label>PF-06671008</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          -  Diagnosis of tumor type with the potential to have P-cadherin expression that is
             resistant to standard therapy or for which no standard therapy is available

          -  Performance status of 0 or 1

          -  Adequate bone marrow, kidney and liver function

        Key Exclusion Criteria

          -  Known CNS disease including, but not limited to, metastases

          -  Current or history of seizure disorder

          -  History of or active autoimmune disorders

          -  Active bacterial, fungal or viral infection

          -  Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study
             treatment

          -  Requirement for systemic immune suppressive medication

          -  Grade 2 or greater peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Sloan Kettering - Westchester Laboratory and Pharmacy</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center- Clinical Trials Office</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas - M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7831001&amp;StudyName=A%20Phase%201%20Dose%20Escalation%20Study%20Evaluating%20The%20Safety%20And%20Tolerability%20Of%20Pf-06671008%20In%20Patients%20With%20Advanced%20Solid%20Tumors</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7831001&amp;StudyName=A+Phase+1+Dose+Escalation+Study+Evaluating+The+Safety+And+Tolerability+Of+Pf-06671008+In+Patients+With+Advanced+Solid+Tumors</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P-cadherin</keyword>
  <keyword>PF-06671008</keyword>
  <keyword>solid tumors</keyword>
  <keyword>lung cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>TNBC</keyword>
  <keyword>CRC</keyword>
  <keyword>neoplasms</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

